---
title: "Curanex Reports GMP, Toxicology Milestones as Phyto-N Readies for Q4 2026 IND"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286424596.md"
description: "Curanex has completed GMP pilot manufacturing and a favorable toxicology study for Phyto-N, aiming for a Q4 2026 IND submission to the FDA for ulcerative colitis. Key highlights include a successful GMP-compliant batch and a 28-day toxicology study with no adverse findings. The company plans to expand its pipeline to include cancer cachexia and reported approximately $4.0 million in cash as of March 31, 2026, to support Phyto-N activities."
datetime: "2026-05-14T13:23:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286424596.md)
  - [en](https://longbridge.com/en/news/286424596.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286424596.md)
---

# Curanex Reports GMP, Toxicology Milestones as Phyto-N Readies for Q4 2026 IND

**Curanex reported completion of GMP pilot manufacturing and a favorable dose-range toxicology study as it advances Phyto-N toward a planned Q4 2026 IND submission.**

**Key Highlights:**

-   Completed GMP‑compliant pilot-scale batch of Phyto-N to support IND‑enabling nonclinical studies and quality control.
-   Finished 28‑day dose‑range toxicology study in rats and dogs with no treatment‑related adverse findings at any dose.
-   Plans a Q4 2026 IND submission to FDA for ulcerative colitis; Phase I trial expected if IND is allowed to proceed.
-   Expanded pipeline strategy to include cancer cachexia as an additional indication for future development.
-   Reported approximately $4.0 million cash as of March 31, 2026 to support near‑term Phyto‑N activities.

Original SEC Filing: Curanex Pharmaceuticals Inc \[ CURX \] - 8-K - May. 14, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [CURX.US](https://longbridge.com/en/quote/CURX.US.md)

## Related News & Research

- [Curanex Pharmaceuticals Inc Q2 2026: Net income $(3.29M), EPS $(0.12) — 10-Q Summary](https://longbridge.com/en/news/295957896.md)
- [iSpecimen ships hundreds of cancer blood specimens for international research order within three weeks](https://longbridge.com/en/news/296531044.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [EIKN: Selective PARP1 and Werner helicase inhibitors show promise for safer, more effective cancer therapy](https://longbridge.com/en/news/296540361.md)
- [11:16 ETBIOSAPIEN - THE REVOLUTIONARY CANCER PLATFORM DEVELOPER - NOMINATED AS "BEST STARTUP" IN THE 2026 PRIX GALIEN USA AWARDS](https://longbridge.com/en/news/295952681.md)